Bionanao Genomics Inc (BNGO)

[Timetravelerdos]

Saphyr’s Value Keeps Increasing
In recent months, new data that increases the value of Bionano’s Saphyr has been frequently released.

For example, in a study of pediatric leukemia patients, Saphyr’s diagnoses were 100% in accordance with those of traditional methods of DNA analysis, Bionano reported on July 14. And in 60% of the patients, the product uncovered “new clinically relevant information, the company stated. It added that:

” the new information that (Saphyr) revealed could represent an opportunity for improved treatment options, patient stratification, or medical care. In addition, these findings uncovered novel gene fusion events that are being explored for prognostic applications in cancer management.”

Moreover, when analyzing “patients with chronic lymphocytic leukemia,” Saphyr was able to produce more information than the commonly used tools in 45% of the patients, Bionano reported. This shows that the product enables more thorough diagnoses than “traditional cytogenetics techniques,” according to the company.

https://www.nasdaq.com/articles/youd-be-wrong-to-paint-bionano-genomics-stock-with-the-meme-stock-brush-2021-07-16